Martin G
Can Fam Physician. 2010; 34:2706-9.
PMID: 20469495
PMC: 2218146.
Ten Eick A, Blumer J, Reed M
Drug Saf. 2001; 24(2):119-47.
PMID: 11235817
DOI: 10.2165/00002018-200124020-00003.
Horak F, Stubner U
Drug Saf. 1999; 20(5):385-401.
PMID: 10348091
DOI: 10.2165/00002018-199920050-00001.
Aaronson D
Drug Saf. 1993; 8(4):321-9.
PMID: 8481218
DOI: 10.2165/00002018-199308040-00006.
Janssens M
Clin Rev Allergy. 1993; 11(1):35-63.
PMID: 8319160
DOI: 10.1007/BF02802293.
Acute and subchronic effects of the H1-histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance.
Brookhuis K, de Vries G, De Waard D
Br J Clin Pharmacol. 1993; 36(1):67-70.
PMID: 8104017
PMC: 1364557.
DOI: 10.1111/j.1365-2125.1993.tb05894.x.
H1-receptor antagonists. Comparative tolerability and safety.
Simons F
Drug Saf. 1994; 10(5):350-80.
PMID: 7913608
DOI: 10.2165/00002018-199410050-00002.
The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers.
Kerr J, Dunmore C, Hindmarch I
Eur J Clin Pharmacol. 1994; 47(4):331-5.
PMID: 7875184
DOI: 10.1007/BF00191164.
Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine. 1984.
Barnett A, Iorio L, Kreutner W, Tozzi S, Ahn H, GULBENKIAN A
Agents Actions. 1994; 43(3-4):149-56; discussion 157.
PMID: 7725966
DOI: 10.1007/BF01986682.
Effects of antihistamine medications on exercise performance. Implications for sportspeople.
Montgomery L, Deuster P
Sports Med. 1993; 15(3):179-95.
PMID: 7680815
DOI: 10.2165/00007256-199315030-00004.
Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects.
Patat A, Stubbs D, Dunmore C, Ulliac N, Sexton B, Zieleniuk I
Eur J Clin Pharmacol. 1995; 48(2):143-50.
PMID: 7589029
DOI: 10.1007/BF00192740.
Lack of effect of astemizole on ethanol dynamics or kinetics.
Bateman D, Chapman P, Rawlins M
Eur J Clin Pharmacol. 1983; 25(4):567-8.
PMID: 6418551
DOI: 10.1007/BF00542130.
The H1-antagonist mequitazine: studies on performance and visual function.
Nicholson A, Stone B
Eur J Clin Pharmacol. 1983; 25(4):563-6.
PMID: 6418550
DOI: 10.1007/BF00542129.
Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine.
Barnett A, Iorio L, Kreutner W, Tozzi S, Ahn H, GULBENKIAN A
Agents Actions. 1984; 14(5-6):590-7.
PMID: 6236679
DOI: 10.1007/BF01978891.
Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy.
Richards D, Brogden R, Heel R, Speight T, Avery G
Drugs. 1984; 28(1):38-61.
PMID: 6204835
DOI: 10.2165/00003495-198428010-00003.
Pharmacologic treatment of rhinitis.
Simons F, Simons K
Clin Rev Allergy. 1984; 2(3):237-53.
PMID: 6149009
DOI: 10.1007/BF02991103.
Comparative trial of two non-sedative H1 antihistamines, terfenadine and astemizole, for hay fever.
Howarth P, Holgate S
Thorax. 1984; 39(9):668-72.
PMID: 6147905
PMC: 459896.
DOI: 10.1136/thx.39.9.668.
Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.
Howarth P, Emanuel M, Holgate S
Br J Clin Pharmacol. 1984; 18(1):1-8.
PMID: 6146346
PMC: 1463581.
DOI: 10.1111/j.1365-2125.1984.tb05013.x.
Treatment of pruritus due to chronic obstructive liver disease.
Duncan J, Kennedy H, Triger D
Br Med J (Clin Res Ed). 1984; 289(6436):22.
PMID: 6145483
PMC: 1442057.
DOI: 10.1136/bmj.289.6436.22.
Effects of two antihistamine drugs on actual driving performance.
Betts T, Markman D, Debenham S, Mortiboy D, McKevitt T
Br Med J (Clin Res Ed). 1984; 288(6413):281-2.
PMID: 6140978
PMC: 1444070.
DOI: 10.1136/bmj.288.6413.281.